A Novel Rational PROTACs Design and Validation via AI-Driven Drug Design Approach
ACS Omega · 17.09.2024 · 9 (37) · 38371-38384
DOI: 10.1021/acsomega.3c10183 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 06.09.2024. Verfasst von Cheng-Li Chou und 3 weiteren Autor:innen. Beteiligte Einrichtung: AnHorn Medicines Co., Ltd., Taipei 115202, Taiwan. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Economic Affairs, Subsidies and Incentives for Taipei Industry.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- AnHorn Medicines Co., Ltd., Taipei 115202, Taiwan.
- Department of Biomedical Engineering, University of California Davis, Davis, California 95616, United States.
ORCID-Profile: Chieh-Te Lin
Förderung
- Ministry of Economic Affairs
- Subsidies and Incentives for Taipei Industry
Zitieren
APA
Chou, C. L., Lin, C. T., Kao, C. T., & Lin, C. C. (2024). A Novel Rational PROTACs Design and Validation via AI-Driven Drug Design Approach. ACS Omega, 9(37), 38371-38384. https://doi.org/10.1021/acsomega.3c10183
Vancouver
Chou CL, Lin CT, Kao CT, Lin CC. A Novel Rational PROTACs Design and Validation via AI-Driven Drug Design Approach. ACS Omega. 2024;9(37):38371-38384. doi:10.1021/acsomega.3c10183
BibTeX
@article{Chou2024,
author = {Chou, Cheng-Li and Lin, Chieh-Te and Kao, Chien-Ting and Lin, Chu-Chung},
title = {A Novel Rational PROTACs Design and Validation via AI-Driven Drug Design Approach},
journal = {ACS Omega},
year = {2024},
volume = {9},
number = {37},
pages = {38371--38384},
doi = {10.1021/acsomega.3c10183}
}
EUVIMED